Albireo Pharma

Loading quotes...

Forecast

The analysts' average price target is €39.30 (-5.10%). The median is €37.52 (-9.39%).

Buy	7
Hold	5
Sell	0

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Albireo Pharma had revenue of €35.68m and net profit of -€133.1m

(EUR)	2021	YoY
Revenue	35.68m	423.11%
Gross profit	34.49m	405.63%
Net profit	-133.1m	36.22%
EBITDA	-17.43m	77.90%

Fundamentals

Metric	Value
Market capitalization	€818.09m
Number of shares	20.74m
52-week high/low	€40.40 - €14.31
Dividends	No
Beta	1.04
P/E ratio	-5.61
PEG ratio	0.02
P/B ratio	4.83
P/S ratio	22.57

Company profile

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Name	Albireo Pharma
CEO	Ronald H. W. Cooper
Headquarters	Boston, ma USA
Website	albireopharma.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	11/05/2007
Employees	130